European regulators look set to approve Samsung Bioepis' biosimilar version of J&J/MSD's Remicade (infliximab) this week, making it the second cut price competitor to the big-selling inflammatory ...

Pfizer is to launch its biosimilar of Johnson & Johnson's blockbuster inflammatory diseases drug Remicade next month in the US. This is only the second biosimilar drug to be launched in the US ...

Several of the top Branded Biologic Drugs along with their associated Biosimilar drugs include: Humira (Adalimumab); Remicade (Infliximab); Rituxan (Rituximab); Enbrel (Etanercept); Herceptin ...

The PLANETRA and PLANETAS studies demonstrate that biosimilars are equivalent in clinical efficacy when compared to Remicade®. From the 1 st July 2015, the gastroenterology department at NBT ...

Experts explored the latest trends, approvals, and pipeline developments in cell and gene therapies, rare disease, immunology ...

About two-thirds of respondents expect an increase in their facility’s use of biosimilars for Avastin (bevacizumab), Neupogen (filgrastim), Remicade (infliximab), and Rituxan (rituximab), while about ...

Biogen (NASDAQ:BIIB – Free Report) had its target price cut by BMO Capital Markets from $260.00 to $230.00 in a research note ...

The US biosimilar market has grown significantly, with a 97% compound annual growth rate since 2015, but adoption varies across therapeutic areas. Health plan policies play a crucial role in ...

The article by Sarfaraz K. Niazi, PhD, critiques the irrationality surrounding biosimilars, suggesting that regulatory changes and cost reductions in manufacturing could make biosimilars as affordable ...

J&J's Q3 2024 earnings beat expectations with $22.5B in revenue, driven by strong performances from Darzalex, STELARA, and ...